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BAckground: Smoking costs at work affect both employers and employees. These 
costs are a result of a combined loss of productivity, time off work due to illness, 
smoking breaks and increasing insurance costs. oBjectives: This study aims to 
evaluate the economical impact of a 12 week smoking cessation program with 
varenicline from an employer perspective in a medium size Mexican-Corporate set-
ting. Methods: A decision tree was built in order to estimate the two endpoints of 
the program: resource used in terms of costs and productivity gains in labor hours, 
in a three year horizon. Smokers enrolling in the program were assumed to be the 
proportion of people who reported being very much indeed interested on quitting 
smoking in a 2005 UK survey (27%). A promotional cost of a 12 week combo-pack of 
varenicline was provided by the manufacturer. A literature review was performed 
in order to obtain smoking specific data of the country and response rates. Labor 
costs were retrieved from the Mexican National Institute of Statistics and Geography 
(INEGI). A base scenario of a medium sized company (250 employees) was assumed 
to show the potential benefits of the program. results: Assuming a 250 employ-
ees company and a shared proportion of 50% of the costs of the program between 
employees and employers, companies would have to invest US$178 per employee 
only at the first year, and have potential savings of US$228 for each of them after 
3 years. At the same circumstances the net productivity gains per programme 
participant would be in an amount of 70.8 hours. conclusions: This research 
showed that if mexican employers invest in a smoking cessation program, signifi-
cant productivity gains and savings could be reached in a 3 year horizon.
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oBjectives: To assess the relationship between treatment satisfaction and adherence 
in chronic obstructive pulmonary disease (COPD) in European patients, and whether the 
strength of this relationship varies according to country. Methods: Data were taken 
from the 5EU (France, Germany, Italy, Spain, and UK) 2011 National Health and Wellness 
Survey (NHWS), a cross-sectional survey representative of the total adult populations 
in each 5EU country. The current analysis included all respondents taking one or two 
treatments for COPD (including chronic bronchitis, COPD, and emphysema; n= 914). 
Satisfaction with medication was measured using a single item per treatment, and 
averaged for respondents taking two treatments. Adherence was measured using a sin-
gle 4-item Morisky Medication Adherence Scale (MMAS) for all COPD treatments used. 
Spearman correlations were used to assess the relationship when adherence was consid-
ered as an ordinal variable, and binary logistic regressions were used to assess the rela-
tionship between the two constructs when adherence was dichotomized. Regressions 
included age and gender as covariates. results: Bivariate correlations demonstrated 
a modest relationship between satisfaction and adherence within COPD patients across 
the five countries rs = .133, p< 0.001). The strength of this relationship ranged from a low 
of rs = 0.05 in France (p = 0.60) to a high of rs= .37 in Spain (p< 0.001). A significant interac-
tion between country and satisfaction confirmed that the relationship varied by country. 
When the relationship was examined within each country, satisfaction was a signifi-
cant predictor of adherence only in Spain and the UK (both p< 0.05). conclusions: 
Mean level of adherence to COPD treatments differed across European countries. Higher 
satisfaction was generally associated with greater adherence, but the strength of this 
relationship varied. Ensuring treatments are satisfactory to the patient may promote 
greater adherence, but the strength of the impact is likely to vary across populations.
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oBjectives: To identify factors related to adherence after a multifactorial interven-
tion in patients with COPD. Methods: Design: Randomized Controlled Trial (ISRCTN 
15106246) Patients: 146 subjects randomly allocated (random blocks of 4 patients) in 
two groups (intervention group-IG, control group-CG). Intervention components: 1)
Motivational aspects: beliefs-behaviour about COPD (group and individual interviews); 
2) Cognitive aspects: information about illness; and 3) Skills: inhaling techniques train-
ing. Follow-up: 1 year, 5 visits/group. Primary Outcome: adherence (pill/doses count); 
Secondary Outcomes: functional status (spirometry), quality of life (Saint George 
Respiratory Questionnaire-SGRQ); Independent variables: intervention, age, sex, edu-
cational level, comorbidity, COPD severity stage (SEPAR guidelines), prescribed medi-
cation. Statistical analysis: Four partial logistic regression models, fixed- and random 
effects estimation, were carried out, a final model was built considering them. Statistical 
packages SPSS 15.0 and Stata 11.1. results: Predominance of males (91.8%), mean 
age 69.08 years (CI95%,67.58-70.44); low cultural level (78.1%), 32.2% current smokers 
(62.84 pack-years [CI95%,55.34-70.34]), Body Mass Index 30.78 kg/m2 (CI95%,28.78-
32.78), 81.2% mild-moderate severity stage, predominance of obstructive respiratory 
pattern; FEV1 (mean)= 67.58% (CI95%,64.58-71.08), 0.87 exacerbations/year [CI95%, 0.68-
1.06]. Pharmacological treatment: inhaled-beta2-adrenergic (80.1%); inhaled-anticho-
linergic (77.4%); inhaled-corticosteroids (70.5%); mucolitycs (11.6%); xanthine (8.2%); 
oxygen therapy (4.8%); oral-corticosteroids (0.7%). Adherence was 41% (41.2CG/40.8IG). 
oBjectives: To analyze the costs of macrolides use compared to cephalosporines 
for treatment of Acute Bacterial Sinusitis (ABSs) in the era of increasing resist-
ance to Streptococcus pneumoniae. Methods: We used a decision analysis model 
(TreeAge Pro 2013) to perform a cost-minimization and sensitivity analysis to 
determine what level of macrolide resistance in a community would trigger cepha-
losporine use. Costs and clinical outcomes of ABSs were extracted from a system-
atic review of the literature and official local databases. Clinical response was 
derived from prospective clinical trials, investigations and from clinical experts 
experience, were we had ≤ 1 source. results: We have found that the mean cost 
of empirical treatment with macrolides for ABSs was 79 EUR when community 
S. pneumoniae resistance was at 0%; 77 EUR at 10%; 82 EUR at 20% and 88 EUR at 
30%. Cephalosporines were found to be cost-minimizing when the prevalence of 
macrolide resistance to S. pneumoniae exceeded 15%. Sensitivity analysis variables 
that had a significant impact on our cost-minimization threshold included propor-
tion of macrolide resistance to S. pneumoniae, cost of antibiotics and probabilities 
of clinical cure with antibiotics. conclusions: We believe we have performed 
the first cost-based model and sensitivity analysis to determine what level of 
macrolide resistance in the community could trigger a switch of empirical therapy 
for ABSs from macrolides to cephalosporines in Slovakia. Our investigation is 
to our knowledge also locally the first to employ decision analysis to explore 
the relationship between antimicrobial resistance and clinical decision making 
in ABSs. From a payer perspective, cephalosporines appears to be a reasonable 
alternative to macrolides for empirical treatment of ABSs, especially given the 
current prevalence of macrolides resistance among S. pneumoniae in community 
that reached 30% level, nationwide.
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oBjectives: In the treatment of obstructive sleep apnea/hyoponea syndrome 
(OSAHS) moderate patients are primarily offered Continuous Positive Airway 
Pressure (CPAP). This study aims to assess the cost-effectiveness of mandibular 
advancement device (MAD), a commonly suggested alternative, as compared to 
CPAP for moderate OSAHS patients in The Netherlands. Methods: The prognosis 
of a hypothetical cohort of 50-year-old patients with moderate OSAHS was simu-
lated with a Markov model to estimate the costs and quality-adjusted life-years 
(QALYs) for both CPAP and MAD. A distinctive factor incorporated in the model 
was switch of therapy. All input parameters, including the risks of experiencing 
myocardial infarction, stroke and motor vehicle crashes (MVC) were based on lit-
erature and clinical expert opinion. Costs and effects were estimated over a 5-year 
time horizon using a health care provider perspective and were discounted at a 
rate of 4% and 1.5%, respectively. Robustness of the results was investigated with 
several sensitivity and scenario analyses. results: Compared with CPAP, MAD 
is less expensive (€ 4,511 vs. € 5,302) and only slightly less effective (3.44 vs. 3.49 
QALYs) resulting in an incremental cost-effectiveness ratio (ICER) of € 15,393 saved 
per QALY lost. The most influential parameter was the cost of MAD device and its 
titration. Quality-of-life values, compliance rates, costs and the probabilities of 
switching treatment, cardiovascular events and MVC were varied in the scenario 
analyses. Under the majority of the scenarios MAD remained less cost-effective 
compared to CPAP. conclusions: Over a 5-year time horizon, MAD therapy may 
be considered not cost-effective in the treatment of moderate OSAHS patients in 
The Netherlands. Further research on the impact of both treatments on long-term 
risks and improvement in the quality of life is required. Similarly, more long-term 
studies using a uniform compliance definition are needed to inform future cost-
effectiveness analyses.
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oBjectives: Omalizumab offers an alternative to maintenance oral corticosteroids 
(OCS) in the treatment of severe persistent asthma. Despite widespread recognition 
of the adverse effects from OCS, there is little quantitative evidence on their health 
burden or costs. Failing to account for the adverse effects of OCS may underestimate 
the cost-effectiveness of innovative steroid-sparing medicines such as omalizumab. 
This study aims to explore the possibilities for integrating evidence on the burden of 
OCS in cost-effectiveness analysis using omalizumab as a case study. Methods: A 
model was developed to evaluate the long-term cost-effectiveness of omalizumab in 
patients requiring maintenance OCS. Costs were from a health service perspective 
and outcomes were measured as quality-adjusted life years (QALYs). The burden from 
maintenance use of OCS was quantified with population-based approach, with a deci-
sion model and with threshold analysis. results: The incremental cost-effectiveness 
ratio (ICER) was £37,987 per QALY gained, which is above conventional thresholds used 
in the UK. Threshold analysis showed that the annual health losses from maintenance 
use of oral corticosteroids would need to be 0.12 QALYs per year. This is double the 
quantifiable health losses with the population-based approach and with the decision 
model and 10% of the health gains achieved with omalizumab. conclusions: The 
burden from maintenance OCS can be integrated in cost-effectiveness analysis but 
the extent to which these estimates account for their full impact on health depends 
on the approach used and underlying assumptions. The challenges arise from sparse 
randomised evidence, time lag in the adverse effects and unclear relationship between 
risk and long-term steroid load. These are empirical questions which can be answered 
with further research. Such research would be valuable not only for decision making in 
severe asthma but also for other conditions treated with maintenance OCS.
